The ongoing debate over the cost of prescription drugs took another twist as U.S. Sen. Bernie Sanders (I-VT.) has asked the U.S. Department of Veterans Affairs to use emergency powers to break – or override – the patents on high-priced hepatitis C medicines sold by several drug makers, including Gilead Sciences.
The prices have caused a firestorm as both public and private payers complain the treatments are straining their budgets. Sanders notes the VA stopped enrolling veterans who need treatment for hepatitis C due to budget constraints. The agency has already reallocated $400 million on hepatitis C drugs, but needs additional funding.
“I cannot think of another situation where the government-use provision [of the law that allows the VA to break the patents] should be applied,” Sanders wrote in a letter to Robert McDonald, the U.S. Department of Veterans Affairs Secretary. “Our nation’s veterans cannot, and should not, be denied treatment while drug companies rake in billions of dollars in profits.”
Read more....
Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.
Alan Franciscus
Editor-in-Chief
HCV Advocate
Tuesday, May 12, 2015
Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs
Labels:
Bernie Sanders,
Patents,
VA
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment